| Renovo Group plc | |
| Type: | Public limited company |
| Foundation: | October 2000 |
| Location City: | Manchester |
| Location Country: | United Kingdom |
| Key People: | Mark Ferguson (CEO) |
| Num Employees: | 110 |
| Industry: | Biotechnology |
Renovo Group plc was a biopharmaceutical company, which was founded in 1998 and was headquartered in Manchester, United Kingdom. It worked in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.[1] Renovo does not currently have any marketed products. It aimed "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in approximately 2014. Following the failure of its last clinical candidate Juvista, all 100 of Renovo's staff were laid off in 2011.[2] [3] [4]
Although the company stopped all pharmaceutical development it continued as a financial provider. In August 2014, Renovo Group plc was renamed Inspired Capital plc.[5] [6]
Renovo does not currently have any marketed products. Its development pipeline currently includes one drug in phase III clinical development, two drugs in phase II clinical development, and numerous pre-clinical candidates.[7]
| Drug | Phase | Action | |
|---|---|---|---|
| Juvista | Failed[8] | Injected to the wound margins around the time of surgery causes a prevention or reduction of scarring through introduction of recombinant TGFβ3. | |
| Adaprev | Halted[9] | Injected at the time of surgery for the prevention and reduction of scarring and adhesions between the tendon and surrounding tissues following tendon repair.]. | |
| Prevascar | Halted[10] | Injected to the wound margins around the time of surgery causes a reduction of scarring through suppression of TGFβ1 and TGFβ2. | |
| Juvidex | Renovo planned to partner Juvidex as a cosmetic ingredient for the improvement of skin appearance and to promote the healing of damaged skin. | ||
| RN1005 | Phase I Clinical trial | RN1005 is an advanced preclinical candidate pharmaceutical, discovered by Renovo, targeting the Wnt pathway to reduce scarring and enhance tissue regeneration. |